ADRX-0706

Verastem Oncology will present additional analyses from the Phase 2 RAMP 201 trial evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer at SGO 2025, building on their FDA Priority Review submission.

Intravesical therapies like cretostimogene and TAR-200 show promising complete response rates in BCG-unresponsive NMIBC, but duration of response remains a key factor.

Adicet Bio's ADI-001 receives FDA Fast Track designation for refractory systemic lupus erythematosus (SLE) with extrarenal involvement, expediting its development.

Adcendo's ADCE-D01, a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, has received FDA clearance for a Phase I/II trial in metastatic and/or unresectable soft tissue sarcoma (STS).